by ECHO / Published in Education, Scientific Cannabinoid Research

A new study by a renowned neurologist has found THC-free cannabidiol (CBD) hemp oil to effectively reduce the frequency of seizures in 84% of children diagnosed with a severe seizure disorder. Dr. Garza Morales, a specialist in child neurology and epilepsy, announced his findings at a press conference in Mexico last month.

Between January 2016 and February 2017, Dr. Garza examined 39 patients diagnosed with Lennox-Gastaut Syndrome, a rare seizure-causing neurological disorder that most commonly affects young children. The patients in the study had been taking at least three traditional anti-epileptic drugs and had not seen any improvements in seizures. They were given doses of 5 to 7 mg of 100% pure CBD hemp oil per kg of body weight for at least 6 months. The CBD oil was completely free of tetrahydrocannabinol (THC), the well-known psychoactive cannabinoid.

The results of the study revealed that CBD hemp oil significantly reduced the frequency of seizures. Of the 39 participants, 33 experienced a 50% or greater reduction in seizures with the CBD hemp oil treatments. Fifty-three percent of the participants saw a 75% overall reduction in seizure activity. Seven of the patients experienced a complete elimination of seizures for at least 4 months.

The types of seizures found to best respond to the use of pure CBD were atonic, absent, and generalized tonic, which achieved overall reductions from 30% up to 100%. Focal seizures responded less to treatment, achieving reductions of 0% to 70%.

Because Lennox-Gastaut Syndrome causes such frequent seizures, almost all children diagnosed develop learning problems, intellectual disability, and behavioral issues. The study’s findings, however, indicate that CBD may also improve quality of life characteristics in children with severe epilepsy. Life quality benefits were observed in 89% of patients. There was an increased alertness recorded in 43% of patients, improved social interaction in 40%, and increased attention in 30%.

None of the patients reported any adverse side effects.

Dr. Garza is reportedly next going to examine cannabidiol’s potential effects on autism.